Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of R21/Matrix-M malaria vaccine in Kenyan adults, children, and infants
PACTR202105682956280Phase 1Unknown
- Sponsor
- University of Oxford
- Start
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of R21/Matrix-M in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Solicited local reactogenicity, Solicited systemic reactogenicity and 3 more. Status: unknown.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202105682956280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202105682956280.